FDA grants fast-track status for DARA's PhII candidate for chemotherapy-induced neuropathic pain
This article was originally published in Scrip
Executive Summary
DARA Biosciences, a Raleigh, North Carolina-based company, said the US FDA has granted fast-track designation for its investigational drug, KRN5500, as a potential treatment for chemotherapy-induced peripheral neuropathy (CIPN). There is no specific agent for treatment of CIPN. Meanwhile, the US National Cancer Institute has agreed to support a follow-up phase II trial for the drug.